Low-dose azacitidine maintenance therapy after allogeneic stem cell transplantation for high-risk pediatric acute myeloid leukemia

被引：21

作者：

Tamura, Akihiro ^{[1
]}

Ishida, Toshiaki ^{[1
]}

Saito, Atsuro ^{[1
]}

Yamamoto, Nobuyuki ^{[1
]}

Yokoi, Takehito ^{[1
,2
]}

Uemura, Suguru ^{[1
,3
]}

Nino, Nanako ^{[1
,3
]}

Fujiwara, Takahiro ^{[1
]}

Tahara, Teppei ^{[1
]}

Nakamura, Sayaka ^{[1
]}

Kozaki, Aiko ^{[1
]}

Kishimoto, Kenji ^{[1
]}

Hasegawa, Daiichiro ^{[1
]}

Kosaka, Yoshiyuki ^{[1
]}

机构：

[1] Kobe Childrens Hosp, Childrens Canc Ctr, Dept Hematol & Oncol, Kobe, Hyogo, Japan

[2] Osaka Univ Hosp, Dept Pediat, Suita, Osaka, Japan

[3] Kobe Univ Hosp, Dept Pediat, Kobe, Hyogo, Japan

来源：

PEDIATRIC BLOOD & CANCER | 2018年 / 65卷 / 10期

关键词：

acute myeloid leukemia; azacitidine; pediatric; post hematopoietic stem cell transplantation; CONVENTIONAL CARE REGIMENS; REGULATORY T-CELLS; MYELODYSPLASTIC SYNDROME; HYPOMETHYLATING AGENT; ELDERLY-PATIENTS; SALVAGE THERAPY; 5-AZA-2'-DEOXYCYTIDINE; MALIGNANCIES; DECITABINE; RELAPSE;

D O I：

10.1002/pbc.27284

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The dismal prognosis of pediatric acute myeloid leukemia (AML) relapsing after hematopoietic stem cell transplantation (HSCT) requires exploration of novel strategies to prevent relapse. Azacitidine (AZA) maintenance therapy could potentially reduce the recurrence rate post HSCT. Here, we presents the cases of three children with high-risk AML post HSCT who were treated with low-dose AZA maintenance therapy, demonstrating the feasibility of this therapy. Currently, all three are in complete remission for 13-41 months despite their high-risk characteristics. Our encouraging data warrant larger prospective studies to assess the efficacy and safety of low-dose AZA maintenance therapy post HSCT for pediatric patients with high-risk AML.

引用

页数：4

共 50 条

[41] Maintenance Therapy with Low-Dose Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed or Refractory AML or MDS: A Dose and Schedule Finding Study
De Lima, Marcos
Silva, Leandro de Padua
Giralt, Sergio
Komanduri, Krishna
Andersson, Borje S.
Hosing, Chitra
Qazilbash, Muzaffar
Shpall, Elizabeth
Thall, Peter
Zhang, Weiqing
McCormick, Gloria
Wang, Xuemei
Popat, Uday
Soriano, Andres
Alousi, Amin
Champlin, Richard
Garcia-Manero, Guillermo
BLOOD, 2008, 112 (11) : 414 - 414
[42] Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents with Acute Myeloid Leukemia and High-Risk Cytogenetics
Tomizawa, D.
Yoshida, M.
Kondo, T.
Miyamura, T.
Taga, T.
Adachi, S.
Koh, K.
Noguchi, M.
Kakuda, H.
Shiba, N.
Watanabe, K.
Inoue, M.
Hashii, Y.
Atsuta, Y.
Ishida, H.
PEDIATRIC BLOOD & CANCER, 2018, 65 : S85 - S86
[43] Preconditioning intervention prior to allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia
Tachibana, Takayoshi
Izumi, Akihiko
Arai, Shota
Takeda, Takaaki
Hirose, Natsuki
Tamai, Yotaro
Sato, Shuku
Hashimoto, Chizuko
Fujimaki, Katsumichi
Ishii, Ryuji
Sakai, Hirotaka
Yamazaki, Etsuko
Inoue, Yasuyuki
Tanaka, Masatsugu
Nakajima, Hideaki
EXPERIMENTAL HEMATOLOGY, 2025, 144
[44] Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents with Acute Myeloid Leukemia and High-Risk Cytogenetics
Tomizawa, D.
Yoshida, M.
Kondo, T.
Miyamura, T.
Taga, T.
Adachi, S.
Koh, K.
Noguchi, M.
Kakuda, H.
Shiba, N.
Watanabe, K.
Inoue, M.
Hashii, Y.
Atsuta, Y.
Ishida, H.
PEDIATRIC BLOOD & CANCER, 2018, 65 : S192 - S193
[45] Maintenance Azacitidine after Hematopoietic Stem Cell Transplantation for Relapse Prevention in Acute Myeloid Leukemia and Myelodysplastic Syndrome
Americo, Andre Dias
Kerbauy, Mariana Nassif
da Silva, Cinthya Correa
Chapchap, Eduardo Cerello
Teixeira, Larissa
de Souza dos Santos, Fabio Pirse
Feitosa Ribeiro, Andreza Alice
Hamerschlack, Nelson
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S206 - S206
[46] Maintenance Therapy with Azacitadine and Valproic Acid after Allogeneic Stem Cell Transplant in Patients with High-Risk Acute Myelogenous Leukemia
Hagen, Patrick A.
Rodriguez, Tulio E.
Smith, Scott
Tsai, Stephanie
Al-Mansour, Zeina
Adams, William
Parthasarathy, Mala
Stiff, Patrick
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (03) : S70 - S71
[47] Role of Post-Allogeneic Hematopoietic Stem Cell Transplantation Low-Dose Azacitidine for Prevention of Relapse in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Retrospective Analysis
Ali, Naveed
Tomlinson, Benjamin
Patel, Rushang D.
Metheny, Leland
Varela, Juan
Otegbeye, Folashade
Boughan, Kirsten M.
Goldstein, Steven C.
Baer, Linda K.
Balls, Jason Willard
Ahmed, Nausheen
Smith, Megan
Brister, Lauren
Edgar, Cory
Nelson, Megan Marie
Smith, Tori
de Lima, Marcos
Mori, Shahram
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S126 - S127
[48] Low-dose ARAC, donor cells, and GM-CSF for treatment of recurrent acute myeloid leukemia after allogeneic stem cell transplantation
Schmid, C
Schleuning, M
Aschan, J
Ringdén, O
Hahn, J
Holler, E
Hegenbart, U
Niederwieser, D
Dugas, M
Ledderose, G
Kolb, HJ
LEUKEMIA, 2004, 18 (08) : 1430 - 1433
[49] Low-dose ARAC, donor cells, and GM-CSF for treatment of recurrent acute myeloid leukemia after allogeneic stem cell transplantation
C Schmid
M Schleuning
J Aschan
O Ringdén
J Hahn
E Holler
U Hegenbart
D Niederwieser
M Dugas
G Ledderose
H-J Kolb
Leukemia, 2004, 18 : 1430 - 1433
[50] Maintenance Treatment With Low-Dose Decitabine After Allogeneic Hematopoietic Cell Transplantation in Patients With Adult Acute Lymphoblastic Leukemia
Liu, Jia
Jiang, Zhong-Xing
Xie, Xin-Sheng
Wan, Ding-Ming
Cao, Wei-Jie
Wang, Meng
Liu, Zhen-Zhen
Dong, Zhen-Kun
Wang, Hai-Qiong
Lu, Run-Qing
Zhang, Yin-Yin
Cheng, Qian-Qian
Fan, Ji-Xin
Li, Wei
He, Fei
Guo, Rong
FRONTIERS IN ONCOLOGY, 2021, 11

← 1 2 3 4 5 →